TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06350955
Drug: Iron Carboxymaltose
Normalized name: Iron carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose of 500 mg ferric carboxymaltose
Study: NCT04989491
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One single dose of rituximab intravenously (IV)
Study: NCT05056974
Drug: chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 10 mg/dose, twice a week for 8 weeks
Study: NCT05310591
Drug: Nivolumab starting at day -1
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It will include relapsed patients. Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks.~-nivolumab starting at day -1.~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response.
Study: NCT05983432
Drug: BL-B01D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized.
Study: NCT05660720
Drug: Orelabrutinib and placebo (orelabrutinib tablet simulator)
Normalized name: Orelabrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib will be administered as 3 tablets (150mg) and placebo as 5 tablets (250mg)
Study: NCT05660720
Drug: Orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib will be administered as 8 tablets (400mg)
Study: NCT05660720
Drug: Moxifloxacin hydrochloride
Normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin hydrochloride will be administered as 1 tablet (400mg)
Study: NCT06118684
Drug: Verapamil (Part A)
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (CYP3A4/Pgp inhibitor), tablet 40 mg. Part A: Dose: 3 tablets twice daily Days 10 to 18, total daily dose: 240 mg.
Study: NCT06118684
Drug: Midazolam (Part B)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (CYP3A4 substrate) oral solution 1 mg/mL. Part B: Dose: 4 mL as a single dose on Day 1 and Day 24, total daily dose: 4 mg.
Study: NCT06118684
Drug: Digoxin (Part B)
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin (Pgp substrate) tablet 0.25 mg. Part B: Dose: 1 tablet as a single dose on Day 1 and Day 24, total daily dose: 0.25 mg.
Study: NCT04952493
Drug: Anlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.
Study: NCT04952493
Drug: Sodium Iodide I 131
Normalized name: Sodium Iodide I 131 Oral Kit
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAI treatment may shrink the tumor
Study: NCT05917561
Drug: Anifrolumab Infusion Product
Normalized name: anifrolumab Injectable Product
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab 300mg/month infusion for 36 weeks
Study: NCT05069857
Drug: Camrelizumab (anti-PD-1 inhibitor)
Normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patients will receive three cycles of Camrelizumab, with 14 days each. 200mg of Carrelizumab will be used intravenously on the first day of each cycle.
Study: NCT05069857
Drug: Apatinib (anti-VEGFR inhibitor)
Normalized name: anti-inhibitor coagulant complex
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle.
Study: NCT06486623
Drug: Chokeberry fiber in capsules
Normalized name: fiber
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group: placebo product - chokeberry fiber (placebo capsules, which were made from chokeberry fiber).~The producer of all capsules is MLD Biotrade in Poznan.
Study: NCT05416762
Drug: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg
Normalized name: vortioxetine Oral Tablet
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg
Study: NCT04952493
Drug: Penpulimab
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
Study: NCT05416762
Drug: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg
Normalized name: vortioxetine Oral Tablet
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg
Study: NCT05416762
Drug: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
Normalized name: vortioxetine Oral Tablet
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
Study: NCT05831449
Drug: Local anesthetic injection of CPL-01
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
Study: NCT05527548
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The oral ALN is the first-line therapy for osteoporosis, and it has been proven that once-weekly ALN 70 mg is an effective and well-tolerated dose for the treatment of postmenopausal osteoporosis. In this study, after receiving the approval of CREC and the Department of Health, we will purchase ALN from drug store. Previous clinical studies have shown that oral administration of ALN at 70mg/week for 1 year and at 5mg/day for 2 years reduced bone loss in postmenopausal women and patients who underwent total hip arthroplasty, respectively. Therefore, in the proposed study, ALN at the dose of 70mg/week will be given to patients post-ACLR for a duration of 8 weeks.
Study: NCT04069286
Drug: Omeprazole 20Mg Capsule
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparator Group omeprazole, 1 20mg capsule + 1 placebo tablet, once a day, for a period of 4 weeks.
Study: NCT05150691
Drug: Pertuzumab Injection
Normalized name: pertuzumab Injection
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT05150691
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered oral
Study: NCT05150691
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered oral
Study: NCT05115838
Drug: Islatravir
Normalized name: Islatravir
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISL 47, 52, or 57 mg implantable rod placed subdermally on the upper arm.
Study: NCT06520098
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
Study: NCT06520098
Drug: Ibrutinib, Acalabrutinib, Zanubrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMBRUVICA is a kinase inhibitor Acalabrutinib is a selective, irreversible small molecule inhibitor of BTK. Zanubrutinib is BTK inhibitors
Study: NCT03458221
Drug: Letrozole Oral Product
Normalized name: letrozole Oral Product
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 2.5mg tablet - 2.5mg once dailty until progression of disease.
Study: NCT03458221
Drug: Bicalutamide Oral Product
Normalized name: bicalutamide Oral Product
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutatmide 150mg tablet - 150mg once daily until progression of disease.
Study: NCT05772832
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery
Study: NCT05772832
Drug: Remifentanyl
Normalized name: Remifentanyl
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery
Study: NCT03458221
Drug: Everolimus Oral Product
Normalized name: everolimus Oral Product
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 10mg tablet - 10mg once daily until progression of disease.
Study: NCT03458221
Drug: Itraconazole Oral Product
Normalized name: itraconazole Oral Product
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 100mg capsule - 300mg twice daily until progression of disease.
Study: NCT04579757
Drug: Surufatinib and Tislelizumab _ Part 1
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 (all cohorts): oral surufatinib at a dose based on cohort level and intravenous tislelizumab at a 200-mg dose
Study: NCT04579757
Drug: Surufatinib and Tislelizumab _ Part 2
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2 (all cohorts): oral surufatinib at the RP2D dose selected in Part 1 and intravenous tislelizumab at a 200-mg dose
Study: NCT04849650
Drug: Amisulpride IV
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single 10mg IV dose of Amisulpride given over 1 minute
Study: NCT04849650
Drug: Amisulpride Oral Tablet
Normalized name: amisulpride Oral Tablet
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single 10mg dose given as an oral tablet
Study: NCT05907759
Drug: Daratumumab SC
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses) followed by every 2 weeks for a total of 16 weeks (8 doses) followed by every 4 weeks for up to 96 weeks (24 doses)
Study: NCT05093933
Drug: Vericiguat
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.5, 5.0, or 10.0 mg orally once daily
Study: NCT05595083
Drug: intranasal dexmedetomidine group
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive 1.5 ug/kg intranasal dexmedetomidine diluted with saline + infusion saline
Study: NCT05595083
Drug: intravouns dexmedetomidine group
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive 0.1- 0.4 ug/kg intravenous infusion dexmedetomidine + intranasal saline.
Study: NCT04643067
Drug: KPG-818 low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
Study: NCT04643067
Drug: KPG-818 high dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
Study: NCT05609942
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine powder for suspension for intravenous infusion / subcutaneous injection
Study: NCT06614270
Drug: anti-CD19 CAR-NK cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Fludarabine (25 mg/m2 per day) on day -5, -4, and -3, and Cyclophosphamide (500mg/m2 per day) on day -5, -4. Doses of 8×10\^6/kg anti-CD19 IL-10 CAR-NK cells will be infused in each group on Day 0, 3, and 6.
Study: NCT04350177
Drug: IkT-148009
Normalized name: IKT-001Pro
DrugBank: IKT-001Pro (DB17307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration gelatin capsule
Study: NCT05644587
Drug: buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine/naloxone will be used to begin each patient's treatment for opioid use disorder.
Study: NCT05439057
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam is infused at a rate of 0.3 mg/kg/hr from induction of anesthesia until 20 minutes before the end of operation.
Study: NCT05439057
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal saline is infused at a rate of 0.3 ml/kg/hr from induction of anesthesia until 20 minutes before the end of operation.
Study: NCT05234606
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg via intravenous (IV) injection in 21-day cycles
Study: NCT05994807
Drug: DC-806
Normalized name: DCS
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT04430569
Drug: Alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
Study: NCT05994807
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT05994807
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05252364
Drug: HP518 - Dose Escalation
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Dose escalation~Daily oral dosage with the prescribed dose level based on Cohort assignment.
Study: NCT05252364
Drug: HP518 - Dose expansion
Normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2: Dose expansion~Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
Study: NCT06228963
Drug: Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib
Normalized name: Helicobacter pylori
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break) plus Orelabrutinib for 8 weeks (or until progression, intolerable toxicity, death, or withdrawal from the study)
Study: NCT00002375
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002375
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05023070
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol 200 mg
Study: NCT05023070
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol 400 mg
Study: NCT05023070
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Epidiolex 400 mg
Study: NCT06768177
Drug: PRP injection
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ML OF PRP
Study: NCT06768177
Drug: Alprostadil 20 micrograms
Normalized name: alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 ML
Study: NCT06062498
Drug: elacestrant, palbociclib, abemaciclib, ribociclib
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT06498700
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg/h ketamine infusion
Study: NCT06498700
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.1 ug/kg/h dexmedetomidine infusion
Study: NCT05456698
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients who achieved CR/CRi had their InO dose at 1.5mg/m2 per cycle (28days/cycle), with 0.5mg/m2 administered on days 1, 8, and 15.~Patients received treatment for up to two cycles in the absence of disease progression or unacceptable toxicity.
Study: NCT05633745
Drug: NEU-723
Normalized name: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Doses
Study: NCT05268289
Drug: Iptacopan (part 1)
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken for 52 Weeks
Study: NCT05268289
Drug: Iptacopan (part 2)
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken for 52 Weeks
Study: NCT05268289
Drug: Iptacopan + placebo
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken for 52 Weeks
Study: NCT06372457
Drug: Mavacamten
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As per product label
Study: NCT05422885
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks
Study: NCT05422885
Drug: Quercetin
Normalized name: Quercetin
DrugBank: Quercetin (DB04216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks
Study: NCT05904730
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The starting dose of axitinib is 5 mg twice daily by mouth with meals. (reception is desirable at the same time every day)
Study: NCT04916418
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TTP block with initial dose of ropivacaine 0.5% (5 mg / ml) 20 ml per catheter (total volume 40ml), followed by doses of ropivacaine 0.2% (2 mg / ml) 20 ml per catheter every 8 hours until 72 hours from the first dose has passed.
Study: NCT03982030
Drug: Dalbavancin
Normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dalbavancin 1.5g IV at day 0, day 8-10
Study: NCT04916548
Drug: Intravenous Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
Study: NCT05922696
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50.000IU weekly in Group A , or 200.000IU monthly in Group B
Study: NCT00004855
Drug: Lopinavir/Ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00004855
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00004855
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04938583
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/Kg Day 1 (every 21 days) until progression
Study: NCT04938583
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m\^2, Day 1 x 6 cycles (every 21 days)
Study: NCT04938583
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 IV Day 1 x 6 cycles (every 21 days)
Study: NCT00004855
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00004855
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05558280
Drug: Dinutuximab beta
Normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The study treatment will be administered with a continuous intravenous infusion at a dose of 14 mg/mq/day, days 1-5, a total of 60 hours (cumulative dose/cycle: 70 mg/mq). Each cycle lasts 28 days.The treatment phase foresees 5 cycles of Dinutuximab Beta.
Study: NCT05851391
Drug: Burst Suppression EEG Target Intravenous Anesthesia
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (\>50% suppressed/attenuated). After this 24-hour period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
Study: NCT05851391
Drug: Seizure Suppression EEG Target Intravenous Anesthesia
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: is to stop seizures by titrating the anesthetic infusion without suppressing most of the EEG background. This target would be continued for 24 hours. After this 24-hours period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.